Direkt zum Inhalt
Merck

Long term myriocin treatment increases MRP1 transport activity.

The international journal of biochemistry & cell biology (2012-11-28)
Peter Meszaros, Karin Klappe, Annie van Dam, Pavlina T Ivanova, Stephen B Milne, David S Myers, H Alex Brown, Hjalmar Permentier, Dick Hoekstra, Jan W Kok
ZUSAMMENFASSUNG

We investigated the effect of myriocin treatment, which extensively depletes sphingolipids from cells, on multidrug resistance-related protein 1 (MRP1) efflux activity in MRP1 expressing cells and isolated plasma membrane vesicles. Our data reveal that both short term (3 days) and long term (7 days) treatment effectively reduce the cellular sphingolipid content to the same level. Intriguingly, a two-fold increase in MRP1-mediated efflux activity was observed following long term treatment, while short term treatment had no impact. Very similar data were obtained with plasma membrane vesicles isolated from myriocin-treated cells. Exploiting the cell-free vesicle system, Michaelis-Menten analysis revealed that the intrinsic MRP1 activity remained unaltered; however, the fraction of active transporter molecules increased. We demonstrate that the latter effect is due to an enhanced recruitment of MRP1 into lipid raft fractions, thereby promoting MRP1 activity.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Myriocin aus Mycelia sterilia, ≥98% (HPLC), powder
Avanti
20:4 PE, 1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine, chloroform